 |
Investor Relations
|
Vitro Announces New Stem Cell Product to Support Clinical Trials Expanding Vitro’s Pipeline that Includes Patent-Protected Adult Stem Cells
Golden, Colorado—August 11, 2009—Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, known for “Harnessing the Power of Cells,” is announcing the addition of a new serum-free stem cell growth medium to its existing product lineup that includes patented adult stem cell lines. Vitro’s newest advance is added to a roster that includes a recently patented cell line derived from human pancreatic tissue, patents for production of FSH, methods and compositions for production of immortalized human cells, and adult stem cells. Vitro also owns patent-pending technology for stem cell therapy of cancer.
To satisfy its growing customer base, Vitro has launched a convenient online e-commerce catalog and is already taking orders from researchers who need products for stem cell research and clinical trials with human stem cells. The e-commerce approach is the most direct and efficient way to both inform and service Vitro’s existing and potential client list of the rapidly growing catalog of specialized stem cell research tools critical to the advancement of stem cell technology. Vitro’s products are classified as Type I Medical Devices meaning that all usage is non-therapeutic and therefore does not require FDA pre-market approval.
Dr. Joe Nieusma, a Senior Toxicologist and member of Vitro’s SAB said, “We’re excited about all the new Vitro products that are moving rapidly into our pipeline. The newest and recently issued patent affords Vitro an exclusive proprietary position for a new cellular therapy to treat Type I diabetes. Vitro’s new medium for human stem cells adds an important element to our other products: the culture of human stem cells under completely defined conditions necessary for rigorous FDA scrutiny of human clinical trials. Vitro is now one of the only stem cell companies to offer three types of stem cell growth media: low-serum, humanized and now serum-free, animal component-free and defined medium.”
Vitro’s new product is a serum-free, animal component-free medium optimized for human stem cell growth without differentiation while eliminating exposure to potential contamination from serum or animal components. Vitro’s new product shows comparable growth characteristics to serum-containing media while maintaining differentiation capacity of human cord blood-derived mesenchymal stem cells (MSC).
Transplanted adult stem cells are usually derived from bone marrow, umbilical cord blood or peripheral blood. These cells must be purified and cultured to ensure sufficient numbers of authentic stem cells to produce therapeutic benefit. During the culture process, stem cells are maintained under conditions that sustain growth without introduction of differentiation or harmful contamination.
About Vitro Diagnostics, Inc.
Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCBB: VODG; http://www.vitrobiopharma.com), known for “Harnessing the Power of Cells” owns US patents for production of the fertility drug, FSH, immortalization of cells, and adult stem cells. The Company also owns a pending US patent regarding stem cell-based cancer treatments. Vitro recently established a new high tech and regulatory compliant manufacturing, R&D and corporate facility in Golden, Colorado. The current focus is “Tools for Stem Cell and Drug Development™”, a series of commercially available products for use in stem cell research and drug development targeting human mesenchymal stem cells, induced pluripotent stem cells and stem cell-based cancer research. In addition, Vitro’s stem cell technology has shown promise for development of stem cell therapy for diabetes and cancer.
Safe Harbor Statement
Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Dr. James Musick
Chief Executive Officer
Vitro Diagnostics, Inc.
(303) 999-2130
E-mail: jim@vitrodiag.com
MEDIA CONTACT:
Sandra Kay Helsel, Ph.D.
SK Helsel & Associates
Office: 520-325-4636
Cell: 520-390-8184
E-mail: skhelsel@skhelsel.com
Source: Vitro Diagnostics, Inc.